Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-04-06

Clinical Trial Update: Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes [NA]

View source ↗

Summary

Clinical trial update comparing once-weekly trelagliptin with once-daily vildagliptin to assess HbA1c reduction in type 2 diabetes mellitus; currently not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trelagliptin (trelagliptin)
  • Vildagliptin (vildagliptin)

Snippet

Sponsor: PNS Hafeez - Naval Hospital | Conditions: Type 2 Diabetes Mellitus (T2DM) | NA | Status: ACTIVE_NOT_RECRUITING